Novartis' multiple sclerosis drug Gilenya may be able to mitigate a painful side effect of chemotherapy in cancer patients, according to a new preclinical study.
Fresh off winning European backing for broader use--which could prompt more multiple sclerosis patients to switch--Gilenya's ability to protect patients' brains is at center stage at this week's American Academy of Neurology meeting.
The day after showing that two of their respective therapies provided better results with earlier treatments, the companies followed up with analyses of safety and brain volume loss for their oral drugs, both of which have already gained significant market share in treating the disease.
Herewith we bring you our Top 15 Drug Launch Superstars. Some of them will be obvious to anyone who follows the pharma business. They certainly were obvious to us. But choosing the rest was a challenge--one we weren't exactly expecting, based on previous experience. Read the full report >>
Novartis' Gilenya, which a consumer watchdog group last year pegged with safety concerns, is again being called into question after a patient taking the MS drug developed a rare brain infection.
Scientists believe a drug approved to treat multiple sclerosis may also be able to help prevent an unrelated medical condition--heart failure.
Novartis is up against another marketing investigation. A U.S. Attorney's Office in New York has demanded documents and information about its Gilenya promotions, adding to a list of other government probes.
The labeling logo is designed to encourage doctors and patients to report side effects, as part of a new effort to more closely monitor drug safety. The list of 100-plus products includes all new drugs and biologics approved since January 2011.
Novartis is thinking young. The Swiss drugmaker is using a cheeky ad campaign, targeted at 20- and 30-somethings not only in magazines, but via websites and social media. Novartis needs to find a new edge in the MS market, where it faces not only well-established injectable drugs, but two new oral rivals.
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.